Global Value-added Medicines (VAM) Development Service 麻豆原创 Research Report 2025

Publication ID:

PB501259453

Publication Date:

January 8, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Value-added Medicines (VAM) Development Service was valued at US$ 553 million in the year 2024 and is projected to reach a revised size of US$ 1059 million by 2031, growing at a CAGR of 10.5% during the forecast period.
Value-added Medicines Developmen鈥宼鈥� Service usually refers to adding additional value to pharmaceutical products by providing professional technical support, innovative solutions and optimized processes in the drug development and manufacturing process. These services may include the design, synthesis, analysis, optimization, production, quality control and other aspects of drug development to improve drug efficacy, safety, production efficiency and patient experience.
North American market for Value-added Medicines (VAM) Development Service is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Value-added Medicines (VAM) Development Service is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Value-added Medicines (VAM) Development Service in Pharmaceutical Companies is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Value-added Medicines (VAM) Development Service include Altus Drug Development, TIEFENBACHER GROUP, Hyloris Pharmaceuticals SA, Adamed, Colonis, Towa International, Galenicap, Sandoz AG, Adragos Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Value-added Medicines (VAM) Development Service, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Value-added Medicines (VAM) Development Service.
The Value-added Medicines (VAM) Development Service market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Value-added Medicines (VAM) Development Service market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Value-added Medicines (VAM) Development Service companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Altus Drug Development
TIEFENBACHER GROUP
Hyloris Pharmaceuticals SA
Adamed
Colonis
Towa International
Galenicap
Sandoz AG
Adragos Pharma
Segment by Type
Chronic Disease Treatment Drugs
Infectious Disease Treatment Drugs
Tumor Treatment Drugs
Other
Segment by Application
Pharmaceutical Companies
Biotech Companies
Hospitals and Medical Institutions
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Value-added Medicines (VAM) Development Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Value-added Medicines (VAM) Development Service 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Chronic Disease Treatment Drugs
1.2.3 Infectious Disease Treatment Drugs
1.2.4 Tumor Treatment Drugs
1.2.5 Other
1.3 麻豆原创 by Application
1.3.1 Global Value-added Medicines (VAM) Development Service 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical Companies
1.3.3 Biotech Companies
1.3.4 Hospitals and Medical Institutions
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Value-added Medicines (VAM) Development Service 麻豆原创 Perspective (2020-2031)
2.2 Global Value-added Medicines (VAM) Development Service Growth Trends by Region
2.2.1 Global Value-added Medicines (VAM) Development Service 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Value-added Medicines (VAM) Development Service Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Value-added Medicines (VAM) Development Service Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Value-added Medicines (VAM) Development Service 麻豆原创 Dynamics
2.3.1 Value-added Medicines (VAM) Development Service Industry Trends
2.3.2 Value-added Medicines (VAM) Development Service 麻豆原创 Drivers
2.3.3 Value-added Medicines (VAM) Development Service 麻豆原创 Challenges
2.3.4 Value-added Medicines (VAM) Development Service 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Value-added Medicines (VAM) Development Service Players by Revenue
3.1.1 Global Top Value-added Medicines (VAM) Development Service Players by Revenue (2020-2025)
3.1.2 Global Value-added Medicines (VAM) Development Service Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Value-added Medicines (VAM) Development Service 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Value-added Medicines (VAM) Development Service Revenue
3.4 Global Value-added Medicines (VAM) Development Service 麻豆原创 Concentration Ratio
3.4.1 Global Value-added Medicines (VAM) Development Service 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Value-added Medicines (VAM) Development Service Revenue in 2024
3.5 Global Key Players of Value-added Medicines (VAM) Development Service Head office and Area Served
3.6 Global Key Players of Value-added Medicines (VAM) Development Service, Product and Application
3.7 Global Key Players of Value-added Medicines (VAM) Development Service, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Value-added Medicines (VAM) Development Service Breakdown Data by Type
4.1 Global Value-added Medicines (VAM) Development Service Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Value-added Medicines (VAM) Development Service Forecasted 麻豆原创 Size by Type (2026-2031)
5 Value-added Medicines (VAM) Development Service Breakdown Data by Application
5.1 Global Value-added Medicines (VAM) Development Service Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Value-added Medicines (VAM) Development Service Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Value-added Medicines (VAM) Development Service 麻豆原创 Size (2020-2031)
6.2 North America Value-added Medicines (VAM) Development Service 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Value-added Medicines (VAM) Development Service 麻豆原创 Size by Country (2020-2025)
6.4 North America Value-added Medicines (VAM) Development Service 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Value-added Medicines (VAM) Development Service 麻豆原创 Size (2020-2031)
7.2 Europe Value-added Medicines (VAM) Development Service 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Value-added Medicines (VAM) Development Service 麻豆原创 Size by Country (2020-2025)
7.4 Europe Value-added Medicines (VAM) Development Service 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Value-added Medicines (VAM) Development Service 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Value-added Medicines (VAM) Development Service 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Value-added Medicines (VAM) Development Service 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Value-added Medicines (VAM) Development Service 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Value-added Medicines (VAM) Development Service 麻豆原创 Size (2020-2031)
9.2 Latin America Value-added Medicines (VAM) Development Service 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Value-added Medicines (VAM) Development Service 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Value-added Medicines (VAM) Development Service 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Value-added Medicines (VAM) Development Service 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Value-added Medicines (VAM) Development Service 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Value-added Medicines (VAM) Development Service 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Value-added Medicines (VAM) Development Service 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Altus Drug Development
11.1.1 Altus Drug Development Company Details
11.1.2 Altus Drug Development Business Overview
11.1.3 Altus Drug Development Value-added Medicines (VAM) Development Service Introduction
11.1.4 Altus Drug Development Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.1.5 Altus Drug Development Recent Development
11.2 TIEFENBACHER GROUP
11.2.1 TIEFENBACHER GROUP Company Details
11.2.2 TIEFENBACHER GROUP Business Overview
11.2.3 TIEFENBACHER GROUP Value-added Medicines (VAM) Development Service Introduction
11.2.4 TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.2.5 TIEFENBACHER GROUP Recent Development
11.3 Hyloris Pharmaceuticals SA
11.3.1 Hyloris Pharmaceuticals SA Company Details
11.3.2 Hyloris Pharmaceuticals SA Business Overview
11.3.3 Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Development Service Introduction
11.3.4 Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.3.5 Hyloris Pharmaceuticals SA Recent Development
11.4 Adamed
11.4.1 Adamed Company Details
11.4.2 Adamed Business Overview
11.4.3 Adamed Value-added Medicines (VAM) Development Service Introduction
11.4.4 Adamed Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.4.5 Adamed Recent Development
11.5 Colonis
11.5.1 Colonis Company Details
11.5.2 Colonis Business Overview
11.5.3 Colonis Value-added Medicines (VAM) Development Service Introduction
11.5.4 Colonis Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.5.5 Colonis Recent Development
11.6 Towa International
11.6.1 Towa International Company Details
11.6.2 Towa International Business Overview
11.6.3 Towa International Value-added Medicines (VAM) Development Service Introduction
11.6.4 Towa International Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.6.5 Towa International Recent Development
11.7 Galenicap
11.7.1 Galenicap Company Details
11.7.2 Galenicap Business Overview
11.7.3 Galenicap Value-added Medicines (VAM) Development Service Introduction
11.7.4 Galenicap Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.7.5 Galenicap Recent Development
11.8 Sandoz AG
11.8.1 Sandoz AG Company Details
11.8.2 Sandoz AG Business Overview
11.8.3 Sandoz AG Value-added Medicines (VAM) Development Service Introduction
11.8.4 Sandoz AG Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.8.5 Sandoz AG Recent Development
11.9 Adragos Pharma
11.9.1 Adragos Pharma Company Details
11.9.2 Adragos Pharma Business Overview
11.9.3 Adragos Pharma Value-added Medicines (VAM) Development Service Introduction
11.9.4 Adragos Pharma Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.9.5 Adragos Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Altus Drug Development
TIEFENBACHER GROUP
Hyloris Pharmaceuticals SA
Adamed
Colonis
Towa International
Galenicap
Sandoz AG
Adragos Pharma

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.